Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Poor Diagnostic Reproducibility in the Identification of Nonconventional Dysplasia in Colitis Impacts the Application of Histologic Stratification Tools.
Nasreddin N, Jansen M, Loughrey MB, Wang LM, Koelzer VH, Rodriguez-Justo M, Novelli M, Fisher J, Brown MW, Al Bakir I, Hart AL, Dunne P, Graham TA, Leedham SJ. Nasreddin N, et al. Among authors: dunne p. Mod Pathol. 2024 Mar;37(3):100419. doi: 10.1016/j.modpat.2023.100419. Epub 2023 Dec 27. Mod Pathol. 2024. PMID: 38158125 Free article.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M, Johnston PG, Van Schaeybroeck S. Dunne PD, et al. Clin Cancer Res. 2014 Jan 1;20(1):164-75. doi: 10.1158/1078-0432.CCR-13-1354. Epub 2013 Oct 29. Clin Cancer Res. 2014. PMID: 24170546 Free PMC article.
Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.
Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, O'Grady T, Arthur K, Loughrey MB, Allen WL, McDade SS, Waugh DJ, Hamilton PW, Longley DB, Kay EW, Johnston PG, Lawler M, Salto-Tellez M, Van Schaeybroeck S. Dunne PD, et al. Clin Cancer Res. 2016 Aug 15;22(16):4095-104. doi: 10.1158/1078-0432.CCR-16-0032. Epub 2016 May 5. Clin Cancer Res. 2016. PMID: 27151745
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Dunne PD, McArt DG, O'Reilly PG, Coleman HG, Allen WL, Loughrey M, Van Schaeybroeck S, McDade S, Salto-Tellez M, Longley DB, Lawler M, Johnston PG. Dunne PD, et al. Cancer Immunol Res. 2016 Jul;4(7):582-91. doi: 10.1158/2326-6066.CIR-15-0302. Epub 2016 May 13. Cancer Immunol Res. 2016. PMID: 27197062
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
Alvi MA, Loughrey MB, Dunne P, McQuaid S, Turkington R, Fuchs MA, McGready C, Bingham V, Pang B, Moore W, Maxwell P, Lawler M, James JA, Murray GI, Wilson RH, Salto-Tellez M. Alvi MA, et al. Among authors: dunne p. Br J Cancer. 2017 Jul 11;117(2):203-209. doi: 10.1038/bjc.2017.168. Epub 2017 Jun 8. Br J Cancer. 2017. PMID: 28595259 Free PMC article.
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Alderdice M, Dunne PD, Cole AJ, O'Reilly PG, McArt DG, Bingham V, Fuchs MA, McQuaid S, Loughrey MB, Murray GI, Samuel LM, Lawler M, Wilson RH, Salto-Tellez M, Coyle VM. Alderdice M, et al. Mod Pathol. 2017 Sep;30(9):1287-1298. doi: 10.1038/modpathol.2017.47. Epub 2017 Jun 16. Mod Pathol. 2017. PMID: 28621318 Free article.
QuPath: Open source software for digital pathology image analysis.
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW. Bankhead P, et al. Among authors: dunne pd. Sci Rep. 2017 Dec 4;7(1):16878. doi: 10.1038/s41598-017-17204-5. Sci Rep. 2017. PMID: 29203879 Free PMC article.
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.
Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M. Dunne PD, et al. Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568398 Free PMC article.
349 results